Highlights
Advanced Health Intelligence CEO Scott Montgomery to provide a company update on traction with its digital health solutions to the investor community at the Microcap Conference in Atlantic City 30th January to 1st February.
Topics presented will include progress of AHI's Biometric Health Assessment academic validation, geographical focuses and updates on the imminent commercialisation milestones.
Conference presentations and 1:1 meetings to be held on 31 January and 1 February in Atlantic City.
Perth, Australia--(Newsfile Corp. - January 18, 2024) - Advanced Health Intelligence (AHI) Ltd (ASX: AHI) (NASDAQ: AHI), ("Advanced Health Intelligence", "AHI" or the "Company"), a leading digital health technology provider, has announced that CEO Scott Montgomery will be presenting at The Microcap Conference on 31 January and 1 February 2024 in Atlantic City, New Jersey, USA.
Mr. Montgomery will provide updated insights into how the company is leveraging AI in its digital solutions to provide non-invasive biometric scans from a smartphone in approximately 15-minutes, producing comprehensive biometric risk assessments reporting 61 outputs across five major health categories. Adding to technology developments, he will also share updates on commercial partnerships, regulatory and academic validation progress.
Montgomery comments: "We're seeing continued traction with customers and partners interested in driving proactive and personalized health care with our unique and easy to use health risk assessment and stratification tools. In 2024 we are aiming to continue this momentum and bring AHI's biometric health risk assessments to more and more individuals. I'm looking forward to sharing updates to our recent traction announced in the Middle East, South East Asia and the US."
AHI is continuing its momentum in negotiating commercial partnerships with key global health stakeholders. Earlier in January it announced an update on its revenue sharing agreement with Bearn, projecting a revenue share of up to USD $750,000 per month, contingent upon Bearn attaining predicted users from the launch of its User Data Sharing Platform. Additionally, it has recently signed several international agreements including a binding term sheet with Electronic Medical Record and Global Personal Health Record (OnePHR) company OneClinic in Vietnam, a letter of intent with UK insurer Unisure, and, in the Middle East, collaborations with E-Script medicine management company Pharmak Direct, Bin Farhood International Business Management Group L.L.C and IntelliGen FZ-LLC.
Montgomery's presentation sessions will be in Track 5 at 3:15pm Eastern Time on Wednesday, January 31 and 2pm Eastern Time on Thursday, 1 February, in the Dealflow Diamond Lounge, Palladium A, and are open to conference delegates. Additionally, he will be available for 1:1 meetings during the event.
-ENDS-
Contact:
Laura Wilson
Marketing and PR Manager
Advanced Health Intelligence
Laura.wilson@ahi.tech
About Advanced Health Intelligence Ltd
ASX / NASDAQ listed Advanced Health Intelligence Ltd ('AHI') delivers scalable health assessment, risk stratification and digital triage capabilities to healthcare providers, insurers, employers, and government agencies worldwide via our proprietary technology and processes.
Since 2014, AHI has been delivering health-tech innovation via a smartphone, starting with the world's first on-device body dimensioning capability. AHI has developed a patented technology, showcasing the next frontier in digitising healthcare with a suite of componentized solutions, culminating in:
Body dimension and composition assessment to identify the comorbidities of obesity, such as diabetes risk estimates.
Blood biomarker prediction, including HbA1C, HDL, LDL, and 10-year mortality risk.
Transdermal Optical Imaging to return vital signs and cardiovascular disease risk estimates.
On-device dermatological skin identification across 588 skin conditions across 133 categories (Inc. Melanoma); and
Assisting partners in delivering personalized therapeutic and non-therapeutic health coaching to improve daily habits and build health literacy.
Our world-class team of subject matter experts in machine learning, AI, computer vision, and medically trained data scientists ensure that AHI's technology is at the forefront of innovation and the needs of our consumers.
With a focus on impact at scale, AHI is proud to showcase this milestone in digital healthcare transformation, delivering a biometrically derived triage solution accessible on and via a smartphone. With these advanced technologies, AHI helps its partners identify risks across their consumers and triage them into right-care pathways for proactive health management at a population scale.
For more information, please visit:
What is AHI's Biometric Health Assessment, and how does it work?
AHI's Biometric Health Assessment (BHA) is an innovative process made up of BodyScan, FaceScan and Finger PPG that harnesses proprietary algorithms embedded within a smartphone, empowering its sensor and processing capabilities to evaluate an individual's health risks. This comprehensive assessment involves several key steps:
FaceScan: The process begins with facial scans to determine the probability of an individual's blood pressure risk zones. Alongside this, the BHA gathers data like demographic information, daily activity intensity, chronic medication usage, and smoking status.
Photoplethysmogram (PPG) Resting Heart Rate Measurement: In this stage, the user's resting heart rate is captured while in a guided posture, helping further evaluate the baseline heart health.
BodyScan Body Composition Analysis: The smartphone conducts a body scan during this phase, producing waist and hip circumference and body fat percentage.
Cardiovascular Fitness Evaluation: This phase involves an exertion test, then monitoring heart rate recovery. It helps in assessing cardiovascular fitness levels.
Health Risk Assessment Report (HRA) provides an expanded risk assessment to individuals immediately following completion of the BHA. AHI has scientifically validated algorithmic assets that leverage smartphone sensor data from the above phases, to calculate a range of additional measures related to human mortality and morbidity risk including digital blood lipid biomarkers (Cholesterol and triglycerides), inflammation markers, cardiorespiratory fitness and HbA1C. Bottom of Form
Cautionary Note Regarding Forward-Looking Statements:
This news release contains information or statements that constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements, or developments to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by words such as "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.
Forward-looking information may include, without limitation, statements regarding the operations, business, financial condition, expected financial results, performance, prospects, opportunities, priorities, targets, goals, ongoing objectives, milestones, strategies, and outlook of Advance Health Intelligence, and includes statements about, among other things, future developments and the future operations, strengths, and strategies of Advance Health Intelligence. Forward-looking information is provided for the purpose of presenting information about management's current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. These statements should not be read as guarantees of future performance or results.
The forward-looking statements made, or perceived to be made, in this news release are based on management's assumptions and analysis and other factors that may be drawn upon by management to form conclusions and make forecasts or projections, including management's experience and assessments of historical trends, current conditions and expected future developments. Although management believes that these assumptions, analysis, and assessments are reasonable at the time the statements contained in this news release are made, actual results may differ materially from those projected in any forward-looking statements. Examples of risks and factors that could cause actual results to materially differ from forward-looking statements may include: the timing and unpredictability of regulatory actions; regulatory, legislative, legal or other developments with respect to its operations or business; limited marketing and sales capabilities; early stage of the industry and product development; limited products; reliance on third parties; unfavourable publicity or consumer perception; general economic conditions and financial markets; the impact of increasing competition; the loss of key management personnel; capital requirements and liquidity; access to capital; the timing and amount of capital expenditures; the impact of COVID-19; shifts in the demand for Advanced Health Intelligence's products and the size of the market; patent law reform; patent litigation and intellectual property; conflicts of interest; and general market and economic conditions.
The forward-looking information contained in this news release represents the expectations of Advance Health Intelligence as of the date of this news release and, accordingly, is subject to change after such date. Readers should not place undue importance on forward-looking information and should not rely upon this information as of any other date. Advance Health Intelligence undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
To view the source version of this press release, please visit
